Literature DB >> 16508331

Patient selection for IGF-I therapy.

P E Clayton1, O Ayoola, A J Whatmore.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16508331     DOI: 10.1159/000090644

Source DB:  PubMed          Journal:  Horm Res        ISSN: 0301-0163


× No keyword cloud information.
  5 in total

1.  Cognitive function in acromegaly: description and brain volumetric correlates.

Authors:  Caroline Sievers; P G Sämann; H Pfister; C Dimopoulou; M Czisch; J Roemmler; J Schopohl; G K Stalla; J Zihl
Journal:  Pituitary       Date:  2012-09       Impact factor: 4.107

2.  Growth, final height and endocrine sequelae in a UK population of patients with Hurler syndrome (MPS1H).

Authors:  Chris J Gardner; Nicola Robinson; Tim Meadows; Robert Wynn; Andrew Will; Jean Mercer; Heather J Church; Karen Tylee; J Edmond Wraith; Peter E Clayton
Journal:  J Inherit Metab Dis       Date:  2011-01-21       Impact factor: 4.982

3.  Recombinant Human Insulin-Like Growth Factor-1 Treatment: Prime Time or Timeout? [Commentary on "Recombinant Human Insulin Like Growth Factor-1 Treatment: Ready for Prime Time" by Bright GM, Mendoza JR, Rosenfeld RG, Endocrinol Metab Clin N Am 2009; 38:625-38].

Authors:  Arlan L Rosenbloom
Journal:  Int J Pediatr Endocrinol       Date:  2010-02-08

4.  IGF-1 treatment reduces weight loss and improves outcome in a rat model of cancer cachexia.

Authors:  Katja Schmidt; Stephan von Haehling; Wolfram Doehner; Sandra Palus; Stefan D Anker; Jochen Springer
Journal:  J Cachexia Sarcopenia Muscle       Date:  2011-05-08       Impact factor: 12.910

5.  Baseline IGFBP - 3 as the Key Element to Predict Growth Response to Growth Hormone and IGF - 1 Therapy in Subjects with Non - GH Deficient Short Stature and IGF - 1 Deficiency.

Authors:  Sheila Perez-Colon; Oksana Lazareva; Radhika Purushothaman; Shahid Malik; Svetlana Ten; Amrit Bhangoo
Journal:  Int J Endocrinol Metab       Date:  2018-05-21
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.